Journal Article

FZJ-2021-03030

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease

Schemmert, S.FZJ* ; Camargo, L. C.FZJ* ; Honold, D.FZJ* ; Gering, I.FZJ* ; Kutzsche, J.FZJ* ; Willuweit, A.FZJ* ; Willbold, D. (Corresponding author)FZJ*

2021
Molecular Diversity Preservation International Basel

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/28209  doi:10.3390/ijms22126553

Abstract: Multiple sources of evidence suggest that soluble amyloid β (Aβ)-oligomers are responsible for the development and progression of Alzheimer’s disease (AD). In order to specifically eliminate these toxic Aβ-oligomers, our group has developed a variety of all-d-peptides over the past years. One of them, RD2, has been intensively studied and showed such convincing in vitro and in vivo properties that it is currently in clinical trials. In order to further optimize the compounds and to elucidate the characteristics of therapeutic d-peptides, several rational drug design approaches have been performed. Two of these d-peptides are the linear tandem (head-to-tail) d-peptide RD2D3 and its cyclized form cRD2D3. Tandemization and cyclization should result in an increased in vitro potency and increase pharmacokinetic properties, especially crossing the blood–brain-barrier. In comparison, cRD2D3 showed a superior pharmacokinetic profile to RD2D3. This fact suggests that higher efficacy can be achieved in vivo at equally administered concentrations. To prove this hypothesis, we first established the in vitro profile of both d-peptides here. Subsequently, we performed an intraperitoneal treatment study. This study failed to provide evidence that cRD2D3 is superior to RD2D3 in vivo as in some tests cRD2D3 failed to show equal or higher efficacy.

---

Contributing Institute(s):

1. Strukturbiochemie (IBI-7)
2. Physik der Medizinischen Bildgebung (INM-4)

Research Program(s):

1. 323 - Molecular Targets & Therapies (POF4-323) (POF4-323)
2. 5244 - Information Processing in Neuronal Networks (POF4-524) (POF4-524)

Appears in the scientific report 2021

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---